Global Pharmaceutical Tracker, 2022

Global Pharmaceutical Tracker, 2022

Digital Partnerships Focused on Drug Discovery and Development Drive Future Growth Potential

RELEASE DATE
13-Jul-2022
REGION
North America
Research Code: K6F0-01-00-00-00
SKU: HC03560-NA-TC_26703
$2,450.00
In stock
SKU
HC03560-NA-TC_26703
$2,450.00

Pay by invoice

ENQUIRE NOW

Description

This research service offers comprehensive discussions about the key approvals, mergers and acquisitions, product licensing deals, and digital partnerships of the pharmaceutical industry in 2022. A renewed focus on operational excellence and digital transformation will push top-line pharmaceutical industry growth and drive strong partnerships with small and mid-size pharma and digital solution vendors. The digital implosion is transforming the pharma business model to achieve digital maturity. Big pharma is moving toward technology vendor partnerships to accelerate digitization and de-risk investments in in-house capabilities, platforms, and solutions. Diminishing R&D pipelines, stagnant productivity during the last 2 decades, and the disruption in clinical trials due to the pandemic have led to a surge in partnerships. Small and mid-sized companies will continue to attract big pharma and private equity (PE) firms. New modalities and technologies will remain attractive for licensing deals, giving biotech licensor candidates a higher chance of negotiating contract terms and up-front payments.

Table of Contents

Key Highlights

Pharmaceutical Industry—Companies to Watch

New Modality Approvals

New Modality Approvals (continued)

New Modality Approvals (continued)

Key Mergers & Acquisitions

Key Mergers & Acquisitions (continued)

Key Mergers & Acquisitions (continued)

Key In-licensing & Out-licensing Deals 

Key In-licensing & Out-licensing Deals (continued)

Key In-licensing & Out-licensing Deals (continued)

Digital Partnerships

Digital Partnerships (continued)

Digital Partnerships (continued)

Legal Disclaimer

Related Research
This research service offers comprehensive discussions about the key approvals, mergers and acquisitions, product licensing deals, and digital partnerships of the pharmaceutical industry in 2022. A renewed focus on operational excellence and digital transformation will push top-line pharmaceutical industry growth and drive strong partnerships with small and mid-size pharma and digital solution vendors. The digital implosion is transforming the pharma business model to achieve digital maturity. Big pharma is moving toward technology vendor partnerships to accelerate digitization and de-risk investments in in-house capabilities, platforms, and solutions. Diminishing R&D pipelines, stagnant productivity during the last 2 decades, and the disruption in clinical trials due to the pandemic have led to a surge in partnerships. Small and mid-sized companies will continue to attract big pharma and private equity (PE) firms. New modalities and technologies will remain attractive for licensing deals, giving biotech licensor candidates a higher chance of negotiating contract terms and up-front payments.
More Information
Author Delfina Huergo
Industries Healthcare
No Index No
Is Prebook No
Podcast No
WIP Number K6F0-01-00-00-00